Yasir Yousif Elamin: Glad to See Phase 2 NorthStar Trial Cited in The New NCCN Guidelines
Yasir Yousif Elamin/LinkedIn

Yasir Yousif Elamin: Glad to See Phase 2 NorthStar Trial Cited in The New NCCN Guidelines

Yasir Yousif Elamin, Associate Professor of Thoracic Medical Oncology at MD Anderson Cancer Center, shared on LinkedIn:

“Glad to see NorthStar trial cited in the new NCCN NSCLC guidelines. This randomized phase 2 trial showed improved PFS with osimertinib and local consolidation therapy in EGFR mutant lung cancer.

Thank you to our patients, their families and the entire research team.”

NCCN Guidelines.

You can also read: NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC.

Yasir Yousif Elamin